India’s 2017 stent caps coincide with 11% DES growth forecast

India’s 2017 cardiac-stent price caps reduced prices by up to 85% and are associated in the industry disclosure with greater affordability and procedure adoption. Drug-eluting stent (DES) sales volumes in India are forecast to rise from 917,300 devices in 2025 to 1,548,500 in 2030, a compound annual growth rate (CAGR) of 11.0%.

How did India’s 2017 stent price caps change affordability?

India’s 2017 intervention set ceiling prices for cardiac stents and reduced the patient price of the two principal stent categories. The National Pharmaceutical Pricing Authority (NPPA) imposed the caps in 2017, reducing stent prices by up to 85%. The disclosed ceiling price was Rs 7,260 for a bare metal stent (BMS) and Rs 29,600 for a DES; the source describes these prices as revised to Rs 10,510 and Rs 38,267, respectively.

The mechanism identified in the disclosure is greater affordability for patients paying out of pocket, rather than a general expansion in reimbursement. DES are metal stents with polymer coatings that release anti-proliferative drugs locally to reduce restenosis, or re-narrowing caused by scar-tissue growth. NPPA data cited in the disclosure show DES use increased by about 40% after the price cap was introduced, while lower prices potentially increased angioplasty adoption.

The pricing change formed part of a wider post-2017 pattern in emerging economies including India, China, Brazil and Vietnam. Those markets recorded rising procedure volumes despite limited reimbursement because products from multinational companies and emerging companies became more affordable. The price cap was one disclosed factor: cardiovascular disease prevalence, insurance coverage and the adoption of minimally invasive treatment also affect procedure demand.

Why are India’s DES volumes projected to rise 11% a year?

India’s DES sales volume is forecast to grow 11.0% annually from 2025 to 2030 because angioplasty procedure volumes are also expected to increase. Percutaneous coronary intervention (PCI), also called angioplasty with stenting, is a minimally invasive procedure that opens narrowed coronary arteries and commonly involves stent placement. India’s PCI procedure volume is projected to rise from 810,000 in 2025 to about 1.1 million in 2030.

DES volumes are forecast to exceed the procedure count because a normal PCI procedure uses at least 1.2 to 1.6 stents. The estimate of 917,300 DES devices in 2025 compares with 810,000 projected angioplasty procedures, while the 2030 DES projection is 1,548,500 devices. The 11.0% annual volume forecast depends on the projected increase in procedures and continued use of DES in most stenting procedures.

India’s projected growth rate is the highest among the 10 countries in the disclosed volume comparison. China is projected to add 1,339,100 devices between 2025 and 2030, more than India’s projected increase of 631,200 devices. India’s faster percentage growth follows from its smaller 2025 base and the forecast rise in angioplasty procedures.

Why is DES replacing bare metal stents in India?

DES is replacing BMS in India because its drug coating is intended to lower restenosis risk, and DES is the dominant stent type globally. BMS provides structural support but does not have a drug coating, leaving a higher risk of scar-tissue overgrowth inside the stent. The disclosure states that at least 90% of stenting procedures worldwide now use DES.

The market forecast quantifies the product-mix shift in India. India’s DES market is forecast to rise from USD 20.51 crore in 2025 to USD 30.72 crore in 2030, a revenue CAGR of 8.4%, while the BMS market is forecast to decline from USD 6.08 crore to USD 5.37 crore, a negative CAGR of 2.4%. Total coronary-stent demand can therefore grow while the older BMS category contracts.

DES adoption does not remove clinical risks. Stent thrombosis, or clot formation associated with an implanted stent, is described as a potentially fatal angioplasty complication that can arise early after implantation and persist for years. Age, diabetes mellitus, renal failure, congestive heart failure, arterial bifurcations, long lesions and overlapping stents can raise annual risk by about 0.6% to 1.0%.

What do the price caps mean for domestic stent makers?

India’s price caps created a relative opening for domestic manufacturers because the disclosure says domestic producers can make low-cost, quality devices more readily than multinational companies. That distinction matters under a regulated ceiling price, where suppliers must sell within the prescribed price while maintaining their product offering. The disclosure explicitly says the 2017 price cap benefited domestic players relative to multinational companies.

The global DES market remains concentrated among multinational suppliers. Abbott Vascular, Boston Scientific, Medtronic, Teleflex, Biosensors and Terumo together hold more than 90% market share, according to the disclosure. Sahajanand Medical Technologies (SMT) and China’s Lepu Medical have developed advanced products and have a presence in selected geographic regions, creating scope for expansion as demand rises.

Product design is a disclosed competitive variable alongside price. Major DES profiles use sirolimus, everolimus, zotarolimus or biolimus-A9; platforms include cobalt chromium, platinum chromium and stainless steel; and polymers can be bioabsorbable or non-bioabsorbable. The polymer acts as a drug carrier that regulates drug release to the arterial wall, a mechanism intended to prevent restenosis and extend effective treatment.

Conclusion

India’s 2017 stent price caps are associated in the disclosure with affordability-led DES adoption, including an approximately 40% increase in DES use after the intervention. The 2025-2030 forecast combines that affordability backdrop with higher PCI volumes, producing projected DES volume growth of 11.0% annually while BMS revenue declines at 2.4% annually.

The key disclosed measure to watch is whether India’s angioplasty procedure count reaches about 1.1 million in 2030 from 810,000 in 2025, because that expansion underpins the 1,548,500-device DES forecast. SMT’s Sironity sirolimus-coated coronary drug-coated balloon received Drugs Controller General of India approval in 2025 and is under evaluation in a 164-patient Indian post-market clinical follow-up study measuring target lesion failure at 12 months.